Merck Submits Januvia/Metformin NDA Aiming To Launch First Fixed-Dose DPP-4 Inhibitor
Novartis, meanwhile, is positioning its investigational DPP-4 inhibitor Galvus as an add-on to metformin.
Novartis, meanwhile, is positioning its investigational DPP-4 inhibitor Galvus as an add-on to metformin.